Brain metastases at the time of presentation of nonsmall cell lung cancer: a multi-centric AERIO* analysis of prognostic factors

被引:56
作者
Jacot, W [1 ]
Quantin, X
Boher, JM
Andre, F
Moreau, L
Gainet, M
Depierre, A
Quoix, E
Le Chevalier, T
Pujol, JL
机构
[1] Hop Univ Arnaud de Villeneuve, Dept Chest Dis, F-34295 Montpellier 5, France
[2] Hop Univ Arnaud de Villeneuve, Univ Inst Clin Res, Dept Stat & Epidemiol, F-34295 Montpellier 5, France
[3] Inst Gustave Roussy, Inst Canc, Villejuif, France
[4] Hop Univ Strasbourg, Dept Chest Dis, Strasbourg, France
[5] Hop Univ Besancon, Dept Chest Dis, Besancon, France
关键词
brain metastases; non-small cell lung cancer; neuron-specific enolase; prognosis;
D O I
10.1054/bjoc.2000.1706
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A multi-centre retrospective study involving 4 French university institutions has been conducted in order to identify routine pretherapeutic prognostic factors of survival in patients with previously untreated non-small cell lung cancer and brain metastases at the time of presentation. A total of 231 patients were recorded regarding their clinical, radiological and biological characteristics at presentation. The accrual period was January 1991 to December 1998. Prognosis was analysed using both univariate and multivariate (Cox model) statistics. The median survival of the whole population was 28 weeks, Univariate analysis (log-rank), showed that patients affected by one of the following characteristics proved to have a shorter survival in comparison with the opposite status of each variable: male gender, age over 63 years, poor performance status, neurological symptoms, serum neuron-specific enolase (NSE) level higher than 12.5 ng ml(-1), high serum alkaline phosphatase level, high serum LDH level and serum sodium lever below 132 mmol l(-1). In the Cox's model, the following variables were independent determinants of a poor outcome: male gender: hazard ratio (95% confidence interval): 2.29 (1.26-4.16), poor performance status: 1.73 (1.15-2.62), age: 1.02 (1.003-1.043), a high serum NSE level: 1.72 (1.11-2.68), neurological symptoms: 1.63 (1.05-2.54), and a low serum sodium level: 2.99 (1.17-7.62). Apart from 4 prognostic factors shared in common with other stage IV NSCLC patients, whatever the metastatic site (namely sex, age, gender, performance status and serum sodium level) this study discloses 2 determinants specifically resulting from brain metastasis: i.e. the presence of neurological symptoms and a high serum NSE level. The latter factor could be in relationship with the extent of normal brain tissue damage caused by the tumour as has been demonstrated after strokes. Additionally, the observation of a high NSE level as a prognostic determinant in NSCLC might reflect tumour heterogeneity and understimated neuroendocrine differentiation. (C) 2001 Cancer Research Campaign.
引用
收藏
页码:903 / 909
页数:7
相关论文
共 62 条
  • [1] Prognostic factors derived from recursive partition analysis (RPA) of radiation therapy oncology group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases
    Agboola, O
    Benoit, B
    Cross, P
    Da Silva, V
    Esche, B
    Lesiuk, H
    Gonsalves, C
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (01): : 155 - 159
  • [2] SURVIVAL ANALYSIS 1982-1991 - THE 2ND DECADE OF THE PROPORTIONAL HAZARDS REGRESSION-MODEL
    ANDERSEN, PK
    [J]. STATISTICS IN MEDICINE, 1991, 10 (12) : 1931 - 1941
  • [3] Acceptability of patients with brain metastases for clinical trials of chemotherapy for metastatic non-small-cell lung cancer
    Ando, Y
    Sugiura, S
    Ando, M
    Minami, H
    Nomura, F
    Sakai, S
    Shimokata, K
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (05): : 478 - 482
  • [4] [Anonymous], 1982, AM J CLIN PATHOL, V77, P123
  • [5] [Anonymous], LUNG CANC
  • [6] A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis
    Auchter, RM
    Lamond, JP
    Alexander, E
    Buatti, JM
    Chappell, R
    Friedman, WA
    Kinsella, TJ
    Levin, AB
    Noyes, WR
    Schultz, CJ
    Loeffler, JS
    Mehta, MP
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (01): : 27 - 35
  • [7] Brechot JM, 1997, EUR J CANCER, V33, P385, DOI 10.1016/S0959-8049(96)00498-4
  • [8] Serum levels of neuron-specific enolase and s-100 protein after single tonic-clonic seizures
    Büttner, T
    Lack, B
    Jäger, M
    Wünsche, W
    Kuhn, W
    Muller, T
    Przuntek, H
    Postert, T
    [J]. JOURNAL OF NEUROLOGY, 1999, 246 (06) : 459 - 461
  • [9] Prognostic value of histology in patients with non-small cell lung cancer
    Charloux, A
    Hedelin, G
    Dietemann, A
    Ifoundza, T
    Roeslin, N
    Pauli, G
    Quoix, E
    [J]. LUNG CANCER, 1997, 17 (01) : 123 - 134
  • [10] COX DR, 1972, J R STAT SOC B, V34, P187